TAK-994
Clinical data
Routes of
administration
Oral[1]
Drug classOrexin receptor agonist

TAK-994 is an orexin receptor agonist which is under development by Takeda for the treatment of narcolepsy.[2][3] It is a small-molecule and orally active compound and acts as a highly selective agonist of the orexin receptor 2 (OX2) (>700-fold selectivity over the orexin receptor 1 (OX1)).[2][3][4][1] TAK-994 is related to danavorexton (TAK-925).[5] The compound reached phase 2 clinical trials for narcolepsy.[6] However, clinical development was discontinued in October 2021 for safety reasons.[5][7][8][9][10] The chemical structure of TAK-994 has yet to be disclosed.[4]

See also

References

  1. ^ a b Pellitteri G, de Biase S, Valente M, Gigli GL (August 2021). "How treatable is narcolepsy with current pharmacotherapy and what does the future hold?". Expert Opinion on Pharmacotherapy. 22 (12): 1517–1520. doi:10.1080/14656566.2021.1915987. PMID 33882765.
  2. ^ a b Ishikawa T, Suzuki M, Kimura H (April 2020). "0141 A Novel, Orally Available Orexin 2 Receptor-Selective Agonist, TAK-994, Shows Wake-Promoting Effects Following Chronic Dosing in an Orexin-Deficient Narcolepsy Mouse Model". Sleep. 43 (Supplement 1): A56–A56. doi:10.1093/sleep/zsaa056.139. eISSN 1550-9109. ISSN 0161-8105.
  3. ^ a b Thorpy MJ (January 2020). "Recently Approved and Upcoming Treatments for Narcolepsy". CNS Drugs. 34 (1): 9–27. doi:10.1007/s40263-019-00689-1. PMC 6982634. PMID 31953791.
  4. ^ a b Zhang D, Perrey DA, Decker AM, Langston TL, Mavanji V, Harris DL, et al. (June 2021). "Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists". Journal of Medicinal Chemistry. 64 (12): 8806–8825. doi:10.1021/acs.jmedchem.1c00841. PMID 34101446.
  5. ^ a b Jacobson LH, Hoyer D, de Lecea L (January 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. doi:10.1111/joim.13406. PMID 35043499.
  6. ^ Clinical trial number NCT04096560 for "A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy" at ClinicalTrials.gov
  7. ^ "Takeda Provides Update on TAK-994 Clinical Program". Business Wire. 5 October 2021.
  8. ^ "Takeda pauses TAK-994 clinical studies due to safety glitch". The Pharma Letter. 6 October 2021.
  9. ^ Jackson M (6 October 2021). "Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy". Scrip. Informa Pharma Intelligence.
  10. ^ Tong A (6 October 2021). "Takeda flashes red light on 'breakthrough' narcolepsy drug after PhII trials turned up mysterious safety signal". Endpoints News.